Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gneiss, C; Tripp, P; Reichartseder, F; Egg, R; Ehling, R; Lutterotti, A; Khalil, M; Kuenz, B; Mayringer, I; Reindl, M; Berger, T; Deisenhammer, F.
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
Mult Scler. 2006; 12(6):731-737
Doi: 10.1177/1352458506070941
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Khalil Michael
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Interferon beta (IFNbeta) is a first-line therapy for multiple sclerosis (MS). However, some patients experience a decline in efficacy with continued therapy due to the development of anti-IFNbeta neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 MS patients who were receiving IFNbeta-1b, IFNbeta-1a im, or IFNbeta-1a sc. The frequency of NAb in patients receiving IFNbeta-1a im was lower (5%) than in patients treated with any other form of IFNbeta (22-35%) (P < 0.0001). Binding antibodies (BAb) were measured in 808 patients. The frequency differed significantly between treatment groups, ranging from 45% (IFNbeta-1a im) to 88% (IFNbeta-1b). The proportion of NAb-positive patients within the BAb-positive group differed significantly among treatment groups, ranging between 12% (IFNbeta-1a im) and 51% (IFNbeta-1a sc). The median NAb titer from all IFNbeta-1a-treated patients was higher than from IFNbeta-1b-treated patients (446 versus 171 NU/ mL, P = 0.04). Among NAb-positive patients, the frequency of NAb titers > 100 NU/mL was 71% for IFNbeta-1a compared with 58% for IFNbeta-1b (P = 0.04). Except for conflicting data regarding IFNbeta-1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive patients within the BAb-positive group, provide further insight into the immunogenicity of the IFNbeta preparations.
- Find related publications in this database (using NLM MeSH Indexing)
- Adjuvants, Immunologic - administration and dosage
- Antibodies - blood
- Cell Line, Tumor - blood
- Cohort Studies - blood
- Cross-Sectional Studies - blood
- Humans - blood
- Influenza A virus - immunology
- Injections, Intramuscular - immunology
- Injections, Subcutaneous - immunology
- Interferon-beta - administration and dosage
- Lung Neoplasms - administration and dosage
- Multiple Sclerosis, Relapsing-Remitting - drug therapy
- Neutralization Tests - drug therapy
- Seroepidemiologic Studies - drug therapy
- Find related publications in this database (Keywords)
- antibody titer
- IFN beta-1a
- IFN beta-1b
- myxovirus A bioassay
- neutralizing antibodies
- relapsing-remitting multiple sclerosis